About kodiak sciences inc - KOD
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
KOD At a Glance
Kodiak Sciences, Inc.
1250 Page Mill Road
Palo Alto, California 94304
| Phone | 1-650-281-0850 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -229,967,000.00 | |
| Sector | Health Technology | Employees | 124 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
KOD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 10.972 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.97 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.111 |
KOD Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,854,572.581 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
KOD Liquidity
| Current Ratio | 4.718 |
| Quick Ratio | 4.718 |
| Cash Ratio | 4.609 |
KOD Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -66.937 |
| Return on Equity | -149.489 |
| Return on Total Capital | -72.645 |
| Return on Invested Capital | -74.846 |
KOD Capital Structure
| Total Debt to Total Equity | 101.142 |
| Total Debt to Total Capital | 50.284 |
| Total Debt to Total Assets | 45.282 |
| Long-Term Debt to Equity | 93.477 |
| Long-Term Debt to Total Capital | 46.473 |